Impax Asset Management Group plc Cuts Position in Boston Scientific Corporation $BSX

Impax Asset Management Group plc trimmed its holdings in shares of Boston Scientific Corporation (NYSE:BSX) by 1.0% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,449,736 shares of the medical equipment provider’s stock after selling 15,034 shares during the period. Impax Asset Management Group plc’s holdings in Boston Scientific were worth $154,344,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in the business. Police & Firemen s Retirement System of New Jersey lifted its holdings in shares of Boston Scientific by 4.8% during the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 224,434 shares of the medical equipment provider’s stock valued at $24,106,000 after acquiring an additional 10,325 shares in the last quarter. Geode Capital Management LLC increased its holdings in Boston Scientific by 2.0% in the 2nd quarter. Geode Capital Management LLC now owns 32,424,982 shares of the medical equipment provider’s stock valued at $3,466,320,000 after purchasing an additional 622,602 shares in the last quarter. PNC Financial Services Group Inc. raised its position in Boston Scientific by 5.5% in the second quarter. PNC Financial Services Group Inc. now owns 1,215,796 shares of the medical equipment provider’s stock valued at $130,589,000 after purchasing an additional 63,237 shares during the period. Comprehensive Financial Planning Inc. PA acquired a new position in shares of Boston Scientific during the second quarter worth about $180,000. Finally, Tobam boosted its position in shares of Boston Scientific by 12.0% in the second quarter. Tobam now owns 1,334 shares of the medical equipment provider’s stock worth $143,000 after buying an additional 143 shares during the period. Institutional investors and hedge funds own 89.07% of the company’s stock.

Boston Scientific Trading Up 1.6%

NYSE BSX opened at $104.12 on Thursday. The company has a market capitalization of $154.34 billion, a price-to-earnings ratio of 55.68, a price-to-earnings-growth ratio of 2.02 and a beta of 0.58. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.37 and a quick ratio of 0.82. Boston Scientific Corporation has a 12 month low of $85.98 and a 12 month high of $109.50. The company’s fifty day moving average price is $99.85 and its two-hundred day moving average price is $102.54.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.71 by $0.04. Boston Scientific had a net margin of 14.43% and a return on equity of 19.74%. The business had revenue of $5.07 billion for the quarter, compared to analyst estimates of $4.97 billion. During the same quarter in the prior year, the business posted $0.63 EPS. The company’s revenue for the quarter was up 20.3% on a year-over-year basis. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS. Q4 2025 guidance at 0.770-0.790 EPS. As a group, research analysts predict that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Insider Activity at Boston Scientific

In other Boston Scientific news, Director Ellen M. Zane sold 12,891 shares of Boston Scientific stock in a transaction that occurred on Thursday, November 6th. The stock was sold at an average price of $98.28, for a total value of $1,266,927.48. Following the completion of the transaction, the director directly owned 24,134 shares in the company, valued at $2,371,889.52. The trade was a 34.82% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the stock in a transaction on Monday, November 3rd. The stock was sold at an average price of $99.47, for a total value of $4,973,500.00. Following the completion of the sale, the executive vice president directly owned 178,342 shares in the company, valued at $17,739,678.74. This represents a 21.90% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 175,782 shares of company stock worth $17,742,314. Corporate insiders own 0.50% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently commented on BSX shares. UBS Group raised their target price on Boston Scientific from $135.00 to $140.00 and gave the company a “buy” rating in a report on Thursday, October 23rd. Wells Fargo & Company lifted their price objective on shares of Boston Scientific from $124.00 to $125.00 and gave the company an “overweight” rating in a research note on Thursday, October 23rd. Leerink Partners boosted their target price on shares of Boston Scientific from $127.00 to $128.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 1st. Oppenheimer raised shares of Boston Scientific from a “market perform” rating to an “outperform” rating and raised their price target for the company from $118.00 to $125.00 in a report on Monday, September 8th. Finally, Truist Financial lifted their price target on shares of Boston Scientific from $129.00 to $130.00 and gave the stock a “buy” rating in a research note on Thursday, October 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and two have given a Hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $123.77.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.